Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm Study of Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia (Non-M3)

NCT07563179 is registered in ClinicalTrials.gov with Shenzhen University General Hospital as lead sponsor.

NCT NCT07563179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07563179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm Study of Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia (Non-M3)
Lead sponsor
Shenzhen University General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 21, 2026
Completion date
June 30, 2029
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, relapse/recurrence